Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12746771 | 0.78 | MMP2 (0.44) | MMP2MMP3MMP9MMP14FFAR4 | |
| SCHEMBL10238406 | 0.69 | MMP2 (0.46) | MMP2MMP3MMP9MMP14FFAR4 | |
| SCHEMBL12746769 | 0.61 | MMP2 (0.57) | MMP2MMP3MMP9MMP14FFAR4 | |
| SCHEMBL18002608 | 0.60 | ALDH1A3 (0.51) | FFAR4RXRARXRB | |
| SCHEMBL12747850 | 0.59 | HSD17B1 (0.41) | MMP2MMP3MMP9MMP14 | |
| SCHEMBL21944820 | 0.58 | RXRA (0.51) | FFAR4RXRARXRB | |
| SCHEMBL8469211 | 0.57 | RXRA (0.72) | FFAR4RXRARXRB | |
| Biphenyl SCHEMBL27521885 | 0.57 | PTGS2 (0.38) | MMP2MMP14 | |
| SCHEMBL9231778 | 0.56 | CA12 (0.43) | — | |
| SCHEMBL9280337 | 0.56 | RXRA (0.42) | FFAR4RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093287-B2 | Inhibitors of matrix metalloproteinases | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | NOTRE DAME UNIVERSITY (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224275-A1 | INHIBITORS OF MATRIX METALLOPROTEINASES | MMP9, MMP1, MMP2 | MMP2 3/4885MMP3 6/4885MMP9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.